USD 0.88
(-5.44%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -720 Thousand USD | -210.84% |
2022 | -231.62 Thousand USD | -14.15% |
2021 | -202.91 Thousand USD | 98.13% |
2020 | -10.84 Million USD | 13.69% |
2019 | -12.56 Million USD | -18.93% |
2018 | -10.56 Million USD | 16.0% |
2017 | -12.57 Million USD | -2615.74% |
2016 | 500 Thousand USD | 0.0% |
2015 | 500 Thousand USD | 0.0% |
2014 | 500 Thousand USD | 0.0% |
2013 | 500 Thousand USD | 0.0% |
2012 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | -2.81 Million USD | -1481.32% |
2024 Q1 | -178.31 Thousand USD | -26.86% |
2023 Q3 | -198.29 Thousand USD | 93.67% |
2023 FY | -720 Thousand USD | -210.84% |
2023 Q4 | -140.55 Thousand USD | 29.12% |
2023 Q1 | -192.67 Thousand USD | -107.01% |
2023 Q2 | -3.13 Million USD | -1526.76% |
2022 Q3 | -46.59 Thousand USD | -8.46% |
2022 FY | -231.62 Thousand USD | -14.15% |
2022 Q4 | -93.07 Thousand USD | -99.74% |
2022 Q2 | -42.96 Thousand USD | 12.3% |
2022 Q1 | -48.98 Thousand USD | -39.26% |
2021 Q1 | -2.44 Million USD | 8.89% |
2021 FY | -202.91 Thousand USD | 98.13% |
2021 Q2 | -2.46 Million USD | -0.89% |
2021 Q4 | -35.17 Thousand USD | 98.5% |
2021 Q3 | -2.34 Million USD | 5.08% |
2020 Q3 | -2.36 Million USD | 17.42% |
2020 Q4 | -2.68 Million USD | -13.46% |
2020 FY | -10.84 Million USD | 13.69% |
2020 Q2 | -2.86 Million USD | 2.09% |
2020 Q1 | -2.92 Million USD | 0.45% |
2019 Q3 | -3.54 Million USD | -3.38% |
2019 Q1 | -2.64 Million USD | -86.29% |
2019 FY | -12.56 Million USD | -18.93% |
2019 Q4 | -2.94 Million USD | 17.16% |
2019 Q2 | -3.43 Million USD | -29.91% |
2018 Q2 | -4.46 Million USD | -70.81% |
2018 Q1 | -2.61 Million USD | 15.14% |
2018 FY | -10.56 Million USD | 16.0% |
2018 Q4 | -1.41 Million USD | 31.21% |
2018 Q3 | -2.06 Million USD | 53.85% |
2017 Q4 | -3.08 Million USD | 4.37% |
2017 FY | -12.57 Million USD | -2615.74% |
2017 Q3 | -3.22 Million USD | -10.34% |
2017 Q2 | -2.92 Million USD | -2437.3% |
2017 Q1 | 125 Thousand USD | 0.0% |
2016 Q4 | 125 Thousand USD | 0.0% |
2016 Q2 | 125 Thousand USD | 0.0% |
2016 FY | 500 Thousand USD | 0.0% |
2016 Q1 | 125 Thousand USD | 0.0% |
2016 Q3 | 125 Thousand USD | 0.0% |
2015 Q4 | 125 Thousand USD | 0.0% |
2015 Q3 | 125 Thousand USD | 0.0% |
2015 Q2 | 125 Thousand USD | 0.0% |
2015 Q1 | 125 Thousand USD | 0.0% |
2015 FY | 500 Thousand USD | 0.0% |
2014 Q3 | 125 Thousand USD | 0.0% |
2014 Q4 | 125 Thousand USD | 0.0% |
2014 FY | 500 Thousand USD | 0.0% |
2014 Q2 | 125 Thousand USD | 0.0% |
2014 Q1 | 125 Thousand USD | 0.0% |
2013 Q1 | 125 Thousand USD | 0.0% |
2013 Q3 | 125 Thousand USD | 0.0% |
2013 Q4 | 125 Thousand USD | 0.0% |
2013 FY | 500 Thousand USD | 0.0% |
2013 Q2 | 125 Thousand USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Atara Biotherapeutics, Inc. | -313 Thousand USD | -130.034% |
Cara Therapeutics, Inc. | 14.79 Million USD | 104.867% |
Editas Medicine, Inc. | -99.52 Million USD | 99.277% |
Heron Therapeutics, Inc. | 10.04 Million USD | 107.17% |
Iovance Biotherapeutics, Inc. | -9.56 Million USD | 92.473% |
Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.003% |
uniQure N.V. | 2.21 Million USD | 132.506% |
Aclaris Therapeutics, Inc. | -85.21 Million USD | 99.155% |
Agios Pharmaceuticals, Inc. | 17.31 Million USD | 104.157% |
Amicus Therapeutics, Inc. | 362.03 Million USD | 100.199% |
bluebird bio, Inc. | -4.03 Million USD | 82.134% |
Blueprint Medicines Corporation | 236.58 Million USD | 100.304% |
Adicet Bio, Inc. | -6.09 Million USD | 88.193% |
Dynavax Technologies Corporation | 182.11 Million USD | 100.395% |
IQVIA Holdings Inc. | 5.23 Billion USD | 100.014% |
Myriad Genetics, Inc. | 476.4 Million USD | 100.151% |
Neurocrine Biosciences, Inc. | 1.84 Billion USD | 100.039% |
Sarepta Therapeutics, Inc. | 1.09 Billion USD | 100.066% |
Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 100.137% |
Verastem, Inc. | -62 Thousand USD | -1061.298% |
Waters Corporation | 1.76 Billion USD | 100.041% |
Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.008% |
Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.005% |
Biogen Inc. | 7.3 Billion USD | 100.01% |
Viking Therapeutics, Inc. | -292 Thousand USD | -146.577% |
Perrigo Company plc | 1.68 Billion USD | 100.043% |
Esperion Therapeutics, Inc. | 73.06 Million USD | 100.985% |
Mettler-Toledo International Inc. | 2.16 Billion USD | 100.033% |
Abeona Therapeutics Inc. | 302 Thousand USD | 338.412% |
Geron Corporation | -123.5 Million USD | 99.417% |
Illumina, Inc. | 2.74 Billion USD | 100.026% |
Homology Medicines, Inc. | -7.22 Million USD | 90.04% |
Nektar Therapeutics | 53.47 Million USD | 101.346% |
Unity Biotechnology, Inc. | -19.69 Million USD | 96.345% |
Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 97.69% |
BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 100.038% |
Sangamo Therapeutics, Inc. | -45.32 Million USD | 98.411% |
Evolus, Inc. | 140.52 Million USD | 100.512% |
Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.006% |
FibroGen, Inc. | 128.9 Million USD | 100.559% |
Agilent Technologies, Inc. | 3.46 Billion USD | 100.021% |
OPKO Health, Inc. | 318.12 Million USD | 100.226% |
Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 100.047% |
Exelixis, Inc. | 1.75 Billion USD | 100.041% |
Anavex Life Sciences Corp. | - USD | Infinity% |
Intellia Therapeutics, Inc. | -398.79 Million USD | 99.819% |
Zoetis Inc. | 5.83 Billion USD | 100.012% |
Axsome Therapeutics, Inc. | 244.53 Million USD | 100.294% |
Kala Pharmaceuticals, Inc. | -303 Thousand USD | -137.625% |
Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 100.092% |
Corcept Therapeutics Incorporated | 475.89 Million USD | 100.151% |
Halozyme Therapeutics, Inc. | 636.89 Million USD | 100.113% |
Insmed Incorporated | 239.63 Million USD | 100.3% |
TG Therapeutics, Inc. | 219.1 Million USD | 100.329% |
Incyte Corporation | 3.44 Billion USD | 100.021% |
Emergent BioSolutions Inc. | 343.9 Million USD | 100.209% |